36 results about "Anti microbial peptide" patented technology

The invention relates to an antimicrobial peptide consisting of the amino acid sequence: RX1WILX2WLRTWX3X4 wherein X1, X2, X3 and X4 are independently selected from K and R, and wherein each amino acid is independently in the L or D configuration, or a salt or solvate thereof. The use of said antimicrobial peptide in the treatment of an infection caused by Gram negative bacteria, Gram positive bacteria, fungi, and / or yeasts, as well as the use of said peptide as an antimicrobial agent for the prevention of contamination of an article or a living tissue by and / or for the decontamination of an article or a living tissue from Gram negative bacteria, Gram positive bacteria, fungi, and / or yeasts are further aspects of the invention.

The present invention is directed to peptidomimetics having antibacterial activity, especially against Gram-negative bacteria. The peptidomimetics of the invention are compounds of the general formula (I), P1-P2-P3-P4-P5-P6-P7-P8-P9-P10-P11-P12-P13-P14-P15-P16 (I) and salts thereof, in particular pharmaceutically acceptable salts thereof, as described in the description and in the claims. The invention is also directed to therapeutic uses of the peptidomimetics for the treatment or prevention of bacterial infections and diseases related to bacterial infections and to non-therapeutic uses of the peptidomimetics for preserving or disinfecting foodstuffs, cosmetics, medicaments or other nutrient-containing materials.

Antimicrobial peptides of general formula X0X1X2C X3X4X5CX6X7X8X9CYX10X11CX12X13 are provided. Also provided are certain formulations containing these peptides and methods of using these peptides for treating skin infections in an animal in need thereof.

An antimicrobial peptide having an amino acid sequence selected from SEQ ID NOs: 2-12 is provided. The antimicrobial peptide has antimicrobial activity against Gram-negative bacteria, Campylobacter jejuni, Escherichia coli, Salmonella enterica subsp. enterica serovar typhimurium, Salmonella enterica subsp. enterica serovar choleraesuis, Klebsiella pneumonica, and / or Enterobacter cloacae. A composition, pharmaceutical composition, food additive, cosmetic composition, or hygine product having an antimicrobial peptide including an amino acid sequence selected from SEQ ID NOs: 2-12 is also provided. A method of treating an infectious disease caused by bacteria including a step of administering a pharmaceutical composition having the antimicrobial peptide as an active ingredient is also provided.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an anti-HPV16 antimicrobial peptide in preparation of an antiviral medicine. The amino acid sequence of the antimicrobial peptide Perceptide-TJ-2 is as shown in SEQ ID NO. 1, and the antimicrobial peptide Perceptide-TJ-2 is an amino acid sequence shown in SEQ ID NO. The invention evaluates the antiviral activity of the antimicrobial peptide Perceptide-TJ-2 on HPV16 in vitro, the antimicrobial peptide Perceptide-TJ-2 can effectively inhibit the infection of HPV16 on cells at a lower concentration, the drug selection index reaches 64.64, and the antimicrobial peptide Perceptide-TJ-2 has a certain application prospect and provides a new possibility for the research and development of anti-HPV treatment drugs.

A method of increasing antimicrobial peptide concentration on the skin is provided. The method includes cleaning skin with at least one of a cleanser and a sanitizer and applying a topical composition to the skin. The topical composition is comprised of one or more polypeptides and natural extracts that increase the concentration of antimicrobial peptides.

An antimicrobial peptide for maintaining the health of scalp microbiome, including one of the following polypeptides (1)-(7): (1) a polypeptide including an amino acid sequence shown in SEQ ID NO: 1, or a polypeptide consisting of amino acid residues of SEQ ID NO: 1; (2) a polypeptide including an amino acid sequence shown in SEQ ID NO: 2, or a polypeptide consisting of amino acid residues of SEQ ID NO: 2; (3) a polypeptide resulting from substitution, deletion, and / or addition of one or more amino acid residues of the polypeptide in (1) or (2); (4) a polypeptide obtained by modifying a N-terminus and / or a C-terminus of the polypeptide in (1) or (2); and (5) a polypeptide having at least 85%, 90%, 95%, 98%, or 99% sequence identity to the amino acid sequence of the polypeptide in (1) or (2). The antimicrobial peptide exhibits excellent safety for treating scalp conditions.

Disclosed herein are methods and compositions for use in controlling citrus greening, citrus canker, or fire blight, wherein the compositions comprise one or more antimicrobial peptides, or one or more polynucleotides encoding for the one or more antimicrobial peptides.

Disclosed herein are methods and compositions for use in controlling citrus greening, citrus canker, or fire blight, wherein the compositions comprise one or more antimicrobial peptides, or one or more polynucleotides encoding for the one or more antimicrobial peptides.

The invention relates to a compound atomized liquid for pet respiratory mucosa and a preparation method thereof. Each 100 mL of the compound atomized liquid is prepared from 0.15 to 0.20 g of a liquorice root extract, 0.18 to 0.25 g of L-lysine hydrochloride, 0.20 to 0.25 g of chitosan oligosaccharide, 0.25 to 0.35 g of yeast-beta-glucan, 0.008 to 0.015 g of EDTA-2Na (Ethylene Diamine Tetraacetic Acid), 0.4 to 0.6 g of trehalose, 0.65 to 0.75 g of sodium chloride, 0.5 to 1.0 mg of micromolecular antimicrobial peptide and the balance of citric acid / phosphate buffer solution. Wherein the molecular weight of the chitosan oligosaccharide is less than or equal to 2000Da; the pH value of the compound atomized liquid is 6.0-7.0; and the osmotic pressure of the compound atomized liquid is 280-320 mOsm / kg. By compounding the natural anti-inflammatory component, the immunopotentiator, the mucosa protective agent and the micromolecular antimicrobial peptide, synergistic treatment is realized, and side effects are reduced.

The present invention provides novel kinocidin peptides comprising a C-terminal portion of a kinocidin, wherein the C-terminal portion encompasses an α-helical secondary structure and further displays antimicrobial activity. The kinocidin peptides of the invention are derived from and correspond to a C-terminal portion of a kinocidin that includes a γκO core and that can be a CXC, CC, or C class chemokine. Structural, physicochemical and functional properties of this novel class of antimicrobial peptides and amino acid sequences of particular kinocidin peptides are also disclosed. The invention also provides related antimicrobial methods.

One aspect of the present disclosure relates to the use of vitrified active agents such as growth factors and / or one or more antimicrobial peptides (AMPs), or other desired active agent, for wound healing as a component of a wound dressing whereby the active agents are vitrified onto one or more polymeric materials, and their release rate regulated by the presence of one or more biodegradable polymeric materials.

This invention discloses an antiviral disinfectant wipe based on the synergistic effect of biocatalytic sterilization and physical membrane disruption, belonging to the field of disinfectant wipe technology. The disinfectant wipe contains the following raw materials in parts by weight: 85-95 parts spunlace nonwoven fabric, 0.08-0.15 parts modified antimicrobial peptides, 1.5-3 parts modified chitosan, 820-930 parts deionized water, 22-28 parts propylene glycol, 18-22 parts glycerin, 6-9 parts sodium cocoyl glycinate, 0.8-1.2 parts citric acid, 0.8-1.0 parts phenoxyethanol, and 4-7 parts aloe vera extract. This antiviral disinfectant wipe focuses on the synergistic effect of physical membrane disruption and catalytic sterilization. The raw material ratio is scientific, containing highly effective components such as modified antimicrobial peptides and modified chitosan, resulting in excellent sterilization and antiviral effects. The preparation process is standardized, with strict pretreatment of the nonwoven fabric, uniform solution dispersion, and controllable product liquid content. The addition of aloe vera extract makes it mild and non-irritating, allowing for flexible storage and high practicality.

Provided are an antimicrobial peptide that is safe and has high stability, a good antimicrobial effect, and a shorter sequence, as well as pharmaceutical composition thereof, which can be used for treating and relieving rosacea, adolescent acne, atopic dermatitis, genital warts, vulval intraepithelial neoplasia, inflammatory responses, inflammatory response syndrome, etc. The antimicrobial polypeptide comprises the amino acid sequence Ac-SRMKKWAKIIEKWRKWH-NH2.

The application belongs to the technical field of biological medicine, and particularly relates to an antimicrobial peptide and application thereof in preparation of products for preventing and / or treating oral diseases. The amino acid sequence of the antimicrobial peptide Perceptide-302 is shown as SEQ ID NO. 1. Experimental results of the application show that the polypeptide can effectively inhibit and kill oral pathogenic bacteria at a low concentration, the minimum inhibitory concentration (MIC) of the polypeptide on six kinds of bacteria, including Streptococcus mutans, Streptococcus sobrinus, Streptococcus sanguis, Streptococcus gordonii, Lactobacillus casei and Lactobacillus acidophilus, is 2.5 μg / mL-5 μg / mL, the minimum bactericidal concentration (MBC) is 5 μg / mL-10 μg / mL, and mechanism research is carried out on the most important clinical Streptococcus mutans. The application provides a new active ingredient and technical approach for developing a new type, efficient and safe oral disease prevention and treatment drug and product.

Antimicrobial SbDef1-type peptides and proteins are disclosed along with compositions comprising the SbDef1-type peptides and proteins and transgenic or genetically edited plants or microorganisms that express the SbDef1-type peptides and proteins to inhibit growth of pathogenic microbes. Such SbDef1-type peptides and proteins, compositions, plants, and microorganisms can provide for inhibition of microbial growth.

The present disclosure pertains to a treatment strategy to combat select bacteria in the gut, such as H. pylori. The strategy uses a probiotic-based system to express and deliver a guided antimicrobial peptide to the gut. The guided antimicrobial peptide is expressed from a hybrid gene that codes for an antimicrobial peptide fused to a guide peptide, the latter binding to a protein of the target bacterium. This technology can eliminate the target bacterium selectively and specifically from the gut microbiota. The specificity of the targeting, being at the strain, species or genus level, depends on the sequence of the guide peptide used to provide the targeting. The treatment can be administered orally, such as by using an ingestible probiotic.

Computational systems and methods are described for identifying new α-helical antimicrobial peptides using a systemic consensus formula. Newly identified α-helical antimicrobial peptides are tested experimentally and show potent microbiocidal activities.

Antimicrobial peptide compounds, pharmaceutical compositions, and methods for their use in inhibiting microbial growth are provided. The methods provided include methods for inhibiting pan drug resistant Acinetobacter baumannii by administering the peptide compounds to a subject. A method is provided for inhibiting pan drug resistant Acinetobacter baumannii with a synergistic combination of peptide compound Acetyl-AS-aib-LRKL-aib-KRLL-amide (SEQ ID NO: 1) and polymyxin B. In other methods, peptide compounds are provided for inhibiting P. gingivalis which is the keystone bacteria of periodontal disease, the 6th most common infectious disease worldwide.

An antimicrobial peptide for maintaining the health of scalp microbiome, including one of the following polypeptides (1)-(7): (1) a polypeptide including an amino acid sequence shown in SEQ ID NO: 1, or a polypeptide consisting of amino acid residues of SEQ ID NO: 1; (2) a polypeptide including an amino acid sequence shown in SEQ ID NO: 2, or a polypeptide consisting of amino acid residues of SEQ ID NO: 2; (3) a polypeptide resulting from substitution, deletion, and / or addition of one or more amino acid residues of the polypeptide in (1) or (2); (4) a polypeptide obtained by modifying a N-terminus and / or a C-terminus of the polypeptide in (1) or (2); and (5) a polypeptide having at least 85%, 90%, 95%, 98%, or 99% sequence identity to the amino acid sequence of the polypeptide in (1) or (2). The antimicrobial peptide exhibits excellent safety for treating scalp conditions.

A method of preventing or treating or controlling a respiratory disease in a bovine by delivering to a lung or trachea of the bovine a composition including a polyplex having one or more mRNA encoded with a molecule selected from lycosylphosphatidylinositol (GPI) complex, antibody immunoglobulin G (IgG), antibody immunoglobulin A (IgA), antibody immunoglobulin M (IgM), antimicrobial peptide Bactenecin 5 (Bac5), antimicrobial peptide Bactenecin 7 (Bac7), bovine myeloid antimicrobial peptide (BMAP-28), lipoxin inducing enzymes, resolvin inducing enzymes, cytokines, CRISPR associated protein 13 (Cas13) enzymes, nanoluciferase (NLuc) proteins, and gene activator, catalytically dead CRISPR-associated protein 9 fused to an activator selected from the group consisting of VP64-p65-Rta transactivation domain (dCas9-VPR), VP64, and VP64-p65-HSF1 on the N terminus and SS18 on the C-terminus, and a polymer prepared by polymerizing a diacrylate monomer; one or more linker monomers; and one or more branching monomers; and end-capping the polymer.

Provided herein is a composition comprising antimicrobial peptide having sequence of SEQ ID 1 and a natural active such that the composition provides 5 log reduction of bacteria in 1 minute. In the said composition the natural active is selected from medium chain fatty acid (6 to 12 carbon atoms) and selective essential oil like eugenol and citronellal from clove oil and citronella oil respectively.

Provided is a novel short antimicrobial peptide. Additionally, the novel short antimicrobial peptide can be used to inhibit microbial growth, and / or promoting wound-healing more effectively.

Disclosed herein are methods of diagnosing, selecting, monitoring, and treating a subject having Alzheimer's disease (AD) or suspected of having AD based on an antimicrobial peptide (AMP) present at a different level than in a control individual.

The present invention is directed to peptidomimetics having antibacterial activity, especially against Gram-negative bacteria. The peptidomimetics of the invention are compounds of the general formula (I),P1-P2-P3-P4-P5-P6-P7-P8-P9-P10-P11-P12-P13-P14-P15-P16                      (I)and salts thereof, in particular pharmaceutically acceptable salts thereof, as described in the description and in the claims. The invention is also directed to therapeutic uses of the peptidomimetics for the treatment or prevention of bacterial infections and diseases related to bacterial infections and to non-therapeutic uses of the peptidomimetics for preserving or disinfecting foodstuffs, cosmetics, medicaments or other nutrient-containing materials.

Compositions and methods for treating malaria are provided, utilizing antimicrobial peptides (AMPs) targeting malaria parasites (particularly Plasmodium falciparum (Pff). The AMPs of the provided compositions and methods penetrate red blood cells infected with the parasites with high selectivity, while sparing non-infected cells, and are characterized by reduced risk of drug resistance. Further provided are novel peptides targeting the malaria parasite Plasmodium falciparum (Pf) which are particularly effective as anti-malaria agents.

Disclosed is use of starch for providing benefit selecting from the group consisting of inducing secretion of anti-microbial peptide, protecting from microbial infection, improving barrier function boosting innate defense, upregulating the gene expression of cathelicidin antimicrobial peptide or the gene expression of human beta-defensin-4.

Disclosed herein are methods of inhibiting the growth, reducing the population, or killing of at least one species of Gram-negative bacteria comprising contacting the bacteria with a composition comprising an effective amount of a Chp peptide, lysin, or lysin-AMP construct or active fragments or variants thereof for a period of time sufficient to inhibit said growth, reduce said population, or kill said at least one species of Gram-negative bacteria. Also disclosed herein are methods of inhibiting a Gram-negative bacteria present in sputum; methods of preventing, disrupting or eradicating a Gram-negative bacterial biofilm; and methods of treating a bacterial infection caused by a Gram-negative bacteria.

Disclosed herein are methods and compositions for use in controlling citrus greening, citrus canker, or fire blight, wherein the compositions comprise one or more antimicrobial peptides, or one or more polynucleotides encoding for the one or more antimicrobial peptides.

The invention relates to bacteriophage encoded enzymes and enzyme variants having antimicrobial activity, to methods of making such enzymes and enzyme variants, and to bacteriostatic and bactericidal methods using such enzyme and enzyme variants.